-Q4 Revenue Exceeds $5 Million for 2nd Time in 2022; Q4 Net Income Increases 12% to $0.25 Million or $0.04 per share- -2022 Revenue Reaches Nearly $20 Million; 2022 Net Income Increases 6-Fold Compared to 2021 to $1.3 Million or $0.21 per share- -Conference Call Friday March 24th at 1:00pm… Read More..

ASHBURN, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces the dosing of the first patient in its open label clinical trial in Netherton Syndrome patients. The trial is… Read More..

Record Paid Membership Growth Adding 136,000 Since January 1, 2023, a 40% Year-Over-Year Increase   Surpassed 2 Million Paid Members**  Current Cash Position of $10 Million and $27 Million in Short Term Assets  Commenced Previously Announced $2 Million Stock Buyback Extends Record Date to April 7, 2023 for its Planned Special Dividend of a Portion of… Read More..